Overtraining Syndrome: Drugs That Cause or Treat It

What Overtraining Syndrome Actually Is

Overtraining syndrome represents a maladaptive response to excessive training load without adequate recovery, producing sustained performance decrements, neuroendocrine disruption, and mood disturbance that persist for weeks to months. The 2013 ECSS/ACSM joint consensus statement distinguishes OTS from functional overreaching (which resolves in days) and nonfunctional overreaching (which resolves in weeks) based on recovery duration and symptom severity [2].

The Overreaching-to-OTS Continuum

Functional overreaching is a deliberate, short-term training strategy. Athletes push beyond baseline, experience temporary fatigue, then supercompensate with improved performance after a taper. Nonfunctional overreaching occurs when recovery fails to match the training stimulus for several weeks, producing performance stagnation and early mood symptoms. OTS sits at the far end: months-long performance decline, hormonal blunting, immune suppression, and psychological breakdown that no amount of additional training can fix [1].

Neuroendocrine Disruption at the Core

The hypothalamic-pituitary-adrenal (HPA) axis shows measurable dysfunction in OTS. A 2003 study in the British Journal of Sports Medicine found that overtrained athletes exhibited a blunted cortisol and ACTH response to insulin tolerance testing compared to well-trained controls, suggesting hypothalamic or pituitary exhaustion rather than adrenal failure [3]. This same blunting pattern appears in growth hormone and prolactin responses, indicating a widespread hypothalamic signaling deficit.

Drugs That Can Cause or Worsen Overtraining Syndrome

Several commonly prescribed medications produce side-effect profiles that overlap substantially with OTS, either by inducing the same physiologic disruptions or by masking early warning signals until the syndrome becomes entrenched.

Fluoroquinolone Antibiotics

Ciprofloxacin, levofloxacin, and moxifloxacin carry an FDA black-box warning for tendinopathy, tendon rupture, and peripheral neuropathy. These drugs damage mitochondrial function and collagen synthesis [4]. An athlete taking a fluoroquinolone course during a heavy training block faces compounded musculoskeletal risk. The resulting tendon pain, fatigue, and exercise intolerance mirror OTS so closely that misdiagnosis is common. If a fluoroquinolone is prescribed during an active training cycle, training volume should drop to <50% of baseline.

Statins and Myopathy Overlap

Atorvastatin, rosuvastatin, and simvastatin cause myalgia in 5% to 10% of users, with exercise-associated muscle damage rates climbing further in physically active populations [5]. A 2012 study in the Journal of the American College of Cardiology found that statin-treated patients had significantly greater creatine kinase (CK) elevations after eccentric exercise compared to controls. For an athlete, this means slower muscle repair, prolonged soreness, and a training-recovery mismatch that can tip into nonfunctional overreaching.

Beta-Blockers

Propranolol, metoprolol, and atenolol blunt the heart rate response to exercise, reduce maximal oxygen uptake by 5% to 15%, and impair thermoregulation [6]. Athletes on beta-blockers often cannot reach prescribed training intensities, experience premature fatigue, and develop mood changes. These effects create a pharmacologic mimicry of OTS. The 2018 European Society of Cardiology guidelines on sports cardiology recommend reassessing beta-blocker necessity in competitive athletes when performance decline is unexplained.

Systemic Corticosteroids

Prednisone and dexamethasone, when used for more than two weeks, produce a catabolic state: muscle protein breakdown accelerates, bone density decreases, sleep architecture deteriorates, and the HPA axis becomes suppressed [7]. These effects directly exacerbate the neuroendocrine dysfunction already present in early-stage OTS. An athlete returning from a corticosteroid taper should expect 2 to 4 additional weeks before resuming baseline training loads, as the HPA axis requires time to recover normal cortisol pulsatility.

Other Contributing Medications

Isotretinoin has been associated with exercise-induced myalgia and arthralgias that limit training capacity. Mefloquine (antimalarial) can cause neuropsychiatric symptoms including insomnia, anxiety, and fatigue that compound overtraining risk during tropical training camps. Proton pump inhibitors (omeprazole, pantoprazole) impair magnesium and iron absorption over time, potentially depleting micronutrients needed for recovery [8].

How Overtraining Syndrome Is Diagnosed

OTS remains a diagnosis of exclusion. No single blood test confirms it. The 2013 ECSS/ACSM consensus requires clinicians to first rule out organic disease (thyroid dysfunction, iron deficiency, viral infection, diabetes, mood disorders) before assigning the OTS label [2].

Clinical Assessment Tools

The Profile of Mood States (POMS) questionnaire and the Recovery-Stress Questionnaire for Athletes (RESTQ-Sport) are validated screening instruments. A sustained increase in the POMS "iceberg profile" inversion (where tension, depression, anger, fatigue, and confusion scores exceed vigor) across 2 or more weeks signals possible OTS. Heart rate variability (HRV) monitoring showing a persistent shift toward sympathetic dominance, even at rest, supports the clinical picture.

Hormonal Provocation Testing

The most specific test involves measuring the cortisol and ACTH response to a maximal exercise bout or an insulin tolerance test. In OTS, these responses are blunted by 30% to 50% compared to the athlete's baseline or normative values [3]. A two-bout maximal exercise test protocol (two exhaustive bouts separated by 4 hours) has been proposed as a practical alternative: overtrained athletes show a further-blunted hormonal response on the second bout, while healthy athletes recover their response [9].

Laboratory Workup to Exclude Mimics

The minimum blood panel should include complete blood count, ferritin (target >30 ng/mL in athletes), TSH, free T4, fasting glucose, creatine kinase, C-reactive protein, and 25-hydroxyvitamin D. Testosterone-to-cortisol ratio, once promoted as an OTS marker, has not demonstrated sufficient sensitivity or specificity in meta-analyses and should not be used in isolation [10].

Pharmacologic Treatments and Supportive Therapies

No drug has received FDA approval for overtraining syndrome. Rest is the primary intervention. Specific pharmacologic agents address the downstream consequences of OTS and may shorten recovery timelines when combined with structured rest.

SSRIs for Mood and Serotonin Disruption

OTS involves documented serotonin and dopamine imbalances. The "central fatigue hypothesis" proposes that elevated free tryptophan-to-branched-chain-amino-acid ratios during prolonged exercise increase brain serotonin synthesis, contributing to the fatigue and mood disruption seen in OTS [11]. When clinical depression accompanies OTS (present in roughly 30% of diagnosed cases according to a 2019 survey of elite athletes published in the British Journal of Sports Medicine), selective serotonin reuptake inhibitors like sertraline (50 to 100 mg/day) or escitalopram (10 to 20 mg/day) are appropriate. These agents carry the advantage of minimal performance interference compared to tricyclics or benzodiazepines.

Melatonin for Sleep Architecture Restoration

Sleep disruption is among the earliest and most persistent OTS symptoms. Nocturnal cortisol elevation and sympathetic overdrive fragment sleep architecture, reducing slow-wave sleep by up to 25% in overtrained athletes [12]. Low-dose melatonin (0.5 to 3 mg, 30 minutes before bed) improves sleep onset latency and sleep quality without next-day sedation. A 2021 meta-analysis in Sleep Medicine Reviews confirmed melatonin's efficacy for sleep onset improvement with a mean reduction of 7.06 minutes in latency across 23 trials (N=2,031).

Iron Repletion

Ferritin levels below 30 ng/mL are common in endurance athletes, particularly female runners, and iron deficiency amplifies every symptom of OTS: fatigue, impaired oxygen transport, reduced erythropoietin signaling, and cognitive fog. Oral ferrous sulfate (325 mg every other day, taken with vitamin C) or intravenous ferric carboxymaltose (for ferritin <15 ng/mL or oral intolerance) should be initiated when deficiency is confirmed. A 2020 Cochrane review found that IV iron improved exercise capacity and reduced fatigue in iron-deficient adults with a mean hemoglobin increase of 0.9 g/dL at 4 weeks.

Vitamin D Supplementation

Vitamin D insufficiency (25-OH-D <30 ng/mL) is present in 56% of athletes training primarily indoors, according to a 2015 study in the Journal of the International Society of Sports Nutrition. Vitamin D modulates immune function, muscle protein synthesis, and mood regulation. Repletion with cholecalciferol 2,000 to 4,000 IU daily (adjusted by baseline level) may support recovery from the immunosuppression and mood disruption of OTS. Serum levels should be rechecked at 8 to 12 weeks.

What About Testosterone Replacement?

Some male athletes with OTS show suppressed total testosterone (often <300 ng/dL) due to HPA axis dysfunction. This is functional hypogonadism driven by the training-recovery mismatch, not primary testicular failure. Exogenous testosterone therapy is not indicated because the hormonal suppression typically reverses within 8 to 16 weeks of adequate rest [13]. Prescribing TRT before confirming persistent hypogonadism after a full recovery period risks masking the underlying problem and, in competitive athletes, violates anti-doping regulations.

Non-Pharmacologic Recovery Strategies

While medications address specific deficits, the backbone of OTS treatment is behavioral. Training must stop or drop to <30% of the pre-OTS volume for a minimum of 6 to 12 weeks.

Periodization and Load Management

The 2013 ECSS/ACSM consensus recommends a phased return-to-training protocol [2]. Phase 1 (weeks 1 to 4): complete rest or only low-intensity activity like walking. Phase 2 (weeks 5 to 8): reintroduce low-intensity sport-specific training at <50% of previous volume. Phase 3 (weeks 9 to 12): gradual escalation guided by HRV, mood questionnaires, and performance benchmarks. Athletes who return too quickly relapse in over 50% of cases.

Nutrition and Caloric Adequacy

Relative energy deficiency in sport (RED-S), previously called the female athlete triad, frequently coexists with OTS. The 2023 International Olympic Committee consensus on RED-S identifies inadequate caloric intake as a driver of hormonal suppression, immune dysfunction, and bone stress injuries. A registered dietitian should audit caloric intake and macronutrient distribution, targeting a minimum of 45 kcal/kg fat-free mass/day during recovery.

Psychological Support

Cognitive behavioral therapy (CBT) is the evidence-based first-line psychological intervention for the compulsive training patterns that precipitate OTS. Athletes with OTS report higher rates of anxiety (34%) and clinical depression (30%) compared to non-overtrained peers [14]. Early referral to a sports psychologist reduces relapse risk and shortens the subjective recovery experience.

When to Seek Medical Evaluation

Any athlete experiencing a performance plateau lasting more than 2 weeks despite adequate sleep (7+ hours) and nutrition should consult a sports medicine physician. Red flags that suggest OTS rather than normal training fatigue include: unexplained resting heart rate elevation of >5 bpm above baseline for >7 consecutive days, recurrent upper respiratory infections (3 or more in 3 months), persistent sleep disruption despite good sleep hygiene, and new-onset mood symptoms (irritability, apathy, or anhedonia) [2].

Early intervention matters. The mean recovery time for OTS diagnosed within 4 weeks of onset is 3 months, while cases left unaddressed for >3 months average 6 to 9 months of recovery, according to data from the Dutch Olympic training centers published in 2019 [15].